Sugi Predict

Sugi Predict / Compounds / SCHEMBL21458311

SCHEMBL21458311

SCHEMBL21458311

COC(=O)c1cc(Br)cc2cnn(Cc3ccc(-c4ccccc4)cc3)c12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPBWR1 P48145 1/20 0.41
▸ FAAH O00519 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ EGLN1 Q9GZT9 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.40
▸ AGTR1 P30556 1/20 0.39
▸ AGTR2 P50052 1/20 0.39
▸ MAPK8 P45983 5/20 0.39
▸ ERCC5 P28715 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ NR4A2 P43354 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30843270 1.00 KMT2A (0.42) KMT2AMEN1NPBWR1FAAHMGLL
SCHEMBL21458333 0.88 NPBWR1 (0.44) KMT2AMEN1NPBWR1FAAHMGLL
SCHEMBL30843297 0.88 NPBWR1 (0.44) KMT2AMEN1NPBWR1FAAHMGLL
SCHEMBL14404449 0.88 GAA (0.39) KMT2AMEN1FAAHAGTR1AGTR2
SCHEMBL25375332 0.87 NPBWR1 (0.44) KMT2AMEN1NPBWR1FAAHSLC6A3
SCHEMBL759935 0.87 NPBWR1 (0.44) KMT2ANPBWR1MAPK8CYP1A2SMN1; SMN2
SCHEMBL30552936 0.84 KDM4E (0.46) NPBWR1SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL24774311 0.84 MEN1 (0.39) KMT2AMEN1NPBWR1FAAHMGLL
SCHEMBL21458245 0.83 NPBWR1 (0.40) KMT2AMEN1NPBWR1FAAHMGLL
SCHEMBL30843282 0.83 NPBWR1 (0.40) KMT2AMEN1NPBWR1FAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 — — US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 — — EP disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 — — US disclosed
CN-112313208-B Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2024-04-19 — — CN disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 — — US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 — — US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 — — US disclosed
EP-3781550-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF Tempest Therapeutics, Inc. (US) 2021-02-24 — — EP disclosed
CN-112313208-A Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2021-02-02 — — CN disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 — — WO disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 — — WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KMT2A 829/4885MEN1 4314/4885NPBWR1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.